Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock Holdings Decreased by BNP Paribas Financial Markets

BNP Paribas Financial Markets lessened its position in Akero Therapeutics, Inc. (NASDAQ:AKRO) by 28.8% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 20,702 shares of the company’s stock after selling 8,370 shares during the quarter. BNP Paribas Financial Markets’ holdings in Akero Therapeutics were worth $594,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Perceptive Advisors LLC raised its stake in Akero Therapeutics by 8.1% during the 2nd quarter. Perceptive Advisors LLC now owns 1,499,897 shares of the company’s stock valued at $35,188,000 after purchasing an additional 112,426 shares during the period. Long Focus Capital Management LLC raised its position in Akero Therapeutics by 119.0% during the second quarter. Long Focus Capital Management LLC now owns 719,604 shares of the company’s stock valued at $16,882,000 after buying an additional 391,000 shares during the period. Emerald Advisers LLC lifted its stake in Akero Therapeutics by 1.8% in the 3rd quarter. Emerald Advisers LLC now owns 524,427 shares of the company’s stock worth $15,046,000 after acquiring an additional 9,175 shares in the last quarter. Propel Bio Management LLC boosted its position in Akero Therapeutics by 4.9% during the 3rd quarter. Propel Bio Management LLC now owns 343,729 shares of the company’s stock worth $9,862,000 after acquiring an additional 15,977 shares during the period. Finally, Simplify Asset Management Inc. grew its stake in Akero Therapeutics by 15.6% during the 3rd quarter. Simplify Asset Management Inc. now owns 283,766 shares of the company’s stock valued at $8,141,000 after acquiring an additional 38,279 shares in the last quarter.

Insider Buying and Selling at Akero Therapeutics

In other Akero Therapeutics news, CEO Andrew Cheng sold 24,992 shares of the business’s stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $31.14, for a total transaction of $778,250.88. Following the completion of the transaction, the chief executive officer now owns 605,417 shares of the company’s stock, valued at $18,852,685.38. The trade was a 3.96 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Catriona Yale sold 15,485 shares of the company’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $32.62, for a total transaction of $505,120.70. Following the sale, the insider now owns 74,158 shares of the company’s stock, valued at $2,419,033.96. This trade represents a 17.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 398,584 shares of company stock worth $12,430,272 over the last three months. Corporate insiders own 7.94% of the company’s stock.

Akero Therapeutics Trading Down 0.5 %

NASDAQ:AKRO opened at $28.89 on Friday. The company has a market capitalization of $2.02 billion, a P/E ratio of -7.70 and a beta of -0.23. The stock’s 50 day moving average price is $30.81 and its 200 day moving average price is $27.08. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. Akero Therapeutics, Inc. has a 52 week low of $15.32 and a 52 week high of $37.00.

Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings results on Friday, November 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.15). On average, research analysts forecast that Akero Therapeutics, Inc. will post -3.96 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Citigroup initiated coverage on shares of Akero Therapeutics in a research report on Monday, November 18th. They issued a “buy” rating and a $65.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Akero Therapeutics in a research report on Monday, November 18th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Akero Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $46.83.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.